NovaSignal Secures $37 Million in Series C1
LOS ANGELES, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, announced today it has closed $37 million in a Series C1 round of funding. The company will use the capital to support NovaSignal’s continued commercial expansion, consistent delivery of product innovation, and new clinical trials to increase indications within and beyond stroke. Launched in April, the fully autonomous and cloud connected NovaSignal Platform is transforming stroke programs across the country by reducing the complexity of performing crucial cerebral assessments. We are excited to once again back NovaSignal and believe that its innovative approach has the potential to revolutionize patient care across a variety of disease areas,” said Nick Grouf, Managing Partner at Alpha Edison. Using cloud computing and data analytics, NovaSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia.
AI & Machine learning